Provinical Governments List Aclasta on Public Drug Plans
Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment options.
"With the announcement of Aclasta available on public and private drug plans, individuals living with osteoporosis in these provinces will have access to another option for the treatment of this debilitating disease," said Dr. Famida Jiwa, president and CEO, Osteoporosis Canada. "While Osteoporosis Canada applauds the many provincial governments for increasing access, the organization continues to work with other provinces and territories to ensure that all patients with osteoporosis have options and access to the medications they need."
The Criteria for Aclasta
All Osteoporosis patients in Ontario, Saskatchewan, British Columbia and New Brunswick covered by their provincial drug plan or by private drug plans now have access to Aclasta, a new treatment for those with osteoporosis at high risk for fracture.
Aclasta is recommended for
The treatment of osteoporosis in postmenopausal women, as a once-yearly intravenous infusion, to reduce the incidence of hip, vertebral and non-vertebral fractures
The treatment to increase bone mineral density in men with osteoporosis, as a once-yearly intravenous infusion
The treatment and prevention of glucocorticoid-induced osteoporosis, to increase bone mineral density, as a once-yearly intravenous infusion
The prevention of postmenopausal osteoporosis in women with osteopenia as a single intravenous infusion
The treatment of Paget's disease of the bone in men and women, as a single-dose intravenous infusion
Special Authority criteria
For women with postmenopausal osteoporosis, for whom oral bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. ., stricture or achalasia).
Since the Special Authorization criteria varies between provinces and plans, it is recommended to patients to discuss reimbursement eligibility with their treating physicians.
Osteoporosis could strike you or someone you love. It is a silent disease that affects nearly two million Canadians. The risk of a major osteoporotic fracture in Canada is among the highest in the world. Yet, despite the high prevalence of fractures, they are often not appropriately assessed or treated, leaving osteoporosis undiagnosed and undertreated. Broken bones are associated with devastating health consequences including pain, decreased quality of life, loss of independence, and even death. Preventing new fractures for those who have already had an osteoporotic fracture is Osteoporosis Canada's top priority. In 2010, Osteoporosis Canada issued new Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada that help physicians and patients better identify the risk of fracture, resulting in better fracture prevention and better management of osteoporosis overall.